Last reviewed · How we verify
NCT01373866: MULTIMODHAL
Multimodal MRI-guided rTMS to Treat Refractory Hallucinations
NA trial testing MagPro X100 repetitive Transcranial Magnetic Stimulation in Hallucinations in 85 participants. Completed in 11 February 2022.
11 February 2022
Quick facts
| Lead sponsor | University Hospital, Lille |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 85 |
| Start date | 15 November 2010 |
| Primary completion | 11 February 2022 |
| Estimated completion | 11 February 2022 |
| Sites | 2 locations across France |
Drugs / interventions tested
- MagPro X100 repetitive Transcranial Magnetic Stimulation
- MagPro X100 repetitive Transcranial Magnetic Stimulation
Conditions studied
- Hallucinations — all drugs for Hallucinations →
- Schizophrenia — all drugs for Schizophrenia →
- Perceptual Disorders — all drugs for Perceptual Disorders →
Sponsor
University Hospital, Lille
Who can join
Adults 13 to 60, any sex, with Hallucinations or Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
* The efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (RCT) * This study will use a combination of different MRI modalities (fMRI and DTI) to define with precision rTMS brain-targets in the case of multisensory hallucinations * The investigators anticipate that multimodal MRI-guided rTMS will allow a significant improvement in the efficacy of neuromodulation treatment of refractory hallucinations
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
fMRI capture of auditory hallucinations: Validation of the two-steps method.
Leroy A, Foucher JR, Pins D, Delmaire C, et al · · 2017 · cited 14× · PMID 28660668 · DOI 10.1002/hbm.23707 -
Non-invasive Brain Stimulation and Auditory Verbal Hallucinations: New Techniques and Future Directions.
Moseley P, Alderson-Day B, Ellison A, Jardri R, et al · · 2015 · cited 11× · PMID 26834541 · DOI 10.3389/fnins.2015.00515
Verify or expand the search:
- PubMed search for NCT01373866
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Lille trials
Trials by the same sponsor.
- NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
- NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
- NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
- NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
- NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01373866 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01373866.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing